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Purpose.To determine the differences in risk factors for retinopathy of prematurity (ROP) in paired twins.Methods.A retrospective
medical record review was performed for all paired twins screened for ROP between 2007 and 2012. Screening was offered to very
low birth weight (≤1500 grams) and preterm (≤32 weeks) neonates. Twins 1 and 2 were categorized based on the order of delivery.
Maternal and neonatal covariates were analyzed using univariate and multivariate regression analyses for both ROP and Type 1
ROP. Results. In 34 pairs of Chinese twins, the mean gestational age (GA) was 30.2 ± 2.0 weeks. In Twin 1, smaller GA (OR = 0.44,
𝑃 = 0.02), higher mean oxygen concentration (OR = 1.34, 𝑃 = 0.03), presence of thrombocytopenia (OR = 1429.60, 𝑃 < 0.0001),
and intraventricular hemorrhage (OR = 18.67, 𝑃 = 0.03) were significant risk factors for ROP. For Twin 2, a smaller GA (OR =
0.45, 𝑃 = 0.03) was the only risk factor. There were no significant risk factors for ROP in Twin 1 or Twin 2 on multivariate analysis.
Conclusion. In Chinese twin pairs, smaller GA was the only common risk factor for ROP while Twin 1 was more susceptible to the
postnatal risks for ROP.
1. Introduction
Retinopathy of prematurity (ROP) is a vasoproliferative
retinal disease targeting low birth weight, preterm neonates
[1]. ROP is one of the leading causes of childhood blindness
worldwide [2]. Several risk factors have been demonstrated
to be associated with the development of ROP including
small gestational age (GA), low birth weight (BW), anemia,
blood transfusion, mechanical ventilation especially with
high concentration of supplementary oxygen (FiO
2
), hypox-
emia, perinatal sepsis, use of inotropes, intraventricular
hemorrhage (IVH), in vitro fertilization (IVF), and multiple
pregnancies [3–7].
There are only a few publications in the literature inves-
tigating the risk factors for ROP development among twin
pairs [8–10]. Paired, preterm twins share the same prenatal
factors and have identical gestational ages; they differ only by
their birth weight and postnatal exposures. Previous studies
have primarily categorized paired twins according to their
BW. In a study by Woo et al. [9], it was shown that there
was no significant effect of BW on ROP development or
on the severity of ROP among twins, while, in Azad et al.’s
[8] series, the heavier twin was found to be at greater risk
for a more severe stage of ROP. The purpose of this study
was to determine the differences in risk factors for ROP
development in paired twins that are categorized by their
order of delivery.
2. Patients and Methods
The study was approved by the Institutional Review Board
of the Hospital Authority of Hong Kong. The study was
conducted in accordance with the Declaration of Helsinki
and no patient personal data was disclosed in the study. The
authors declare no financial or proprietary interests.
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This was a retrospective study conducted at Caritas Med-
ical Centre, Hong Kong, which provides ophthalmological
service to 2 neonatal intensive care units (NICU) for a
population of 1.9 million.
Medical records for consecutive newborns of paired twins
that were screened for ROP between the period of January
2007 and December 2012 were retrieved using the Clinical
Data Record System of the Hospital Authority of Hong Kong.
2.1. ROP Screening Criterion. All preterm babies admitted
to these 2 NICU with a birth weight ≤ 1500 grams and/or
gestational age ≤ 32 weeks were referred to a pediatric
ophthalmologist for evaluation. All eligible preterms were
examined according to the screening protocol recommended
by the Royal College of Ophthalmologists and United
Kingdom-ROP (UK-ROP) guidelines [11, 12]. Subjects were
first screened at 4 to 8 weeks of postnatal age (≥30 weeks
of GA) and were examined weekly to biweekly, until retinal
vascularisation reached zone 3 or feature of established ROP
regression [11]. Our institution has adopted the UK screening
guideline since 1996 since, in Asian countries, severe ROP
can be present even in more mature and heavier babies.
Treatment was diode laser implemented when the disease
progressed to Type 1 ROP as per the “Early treatment for
retinopathy of prematurity” (ETROP) study [13]. The staging
of ROP was recorded according to the revised International
Classification of ROP, including the extent, zone, and pres-
ence or absence of “plus” disease [14].
All examinations were performed by 3 experienced pedi-
atric ophthalmologists (Gordon S. K. Yau, Victor T. Y. Tam,
and Benjamin C. Y. Chu). Each infant was screened by
an indirect ophthalmoscope using a 30-dioptre (D) lens
after full pharmacological pupil dilatation with tropicamide
0.5% and phenylephrine 1% eye drops. A lid speculum with
scleral indentation after topical anesthesia (amethocaine) was
routinely used. All screening was performed under oxygen
saturation monitoring and the screening was temporarily
withheld in case of desaturations.
The inclusion criteria included all preterm Chinese
infants of paired twins irrespective of their ultimate devel-
opment of ROP or Type 1 ROP. Neonates with incomplete
clinical data, non-Chinese ethnicity, and those that deceased
before the completion of ROP screening were excluded.
The primary outcome measures included the severity of
ROP (the extent, zone, and presence or absence of “plus”
disease) as well as the 34 risk factors (both maternal and
neonatal) for the development of ROP as follows.
Antenatal maternal risk factors (Tables 1 and 2):
(i) maternal diseases: preeclampsia (PET), gestational
diabetes mellitus (GDM);
(ii) IVF;
(iii) use of antenatal steroid (ANS);
(iv) preterm premature rupture of membrane.
Neonatal risk factors (Tables 1 and 2):
(i) demographic information (GA, BW, and gender);
(ii) Apgar scores at 1, 5, and 10 minutes;
(iii) postnatal interventions: surfactant administration;
mechanical ventilation; use of supplementary oxy-
gen; maintenance FiO
2
; use of nonsteroidal anti-
inflammatory agents (NSAID) for patent ductus arte-
riosus (PDA) closure; blood transfusion; photother-
apy; and total parental nutrition (TPN);
(iv) neonatal diseases: respiratory distress syndrome
(RDS); bronchopulmonary dysplasia; postnatal hy-
potension; congenital heart disease; PDA; anemia
(defined as hemoglobin of <110 grams/litre, hemat-
ocrit < 25%); thrombocytopenia; neonatal jaundice
(NNJ); IVH; necrotizing enterocolitis (NEC); hypo-
glycaemia; sepsis (culture positive or use of antibiotics
for more than 7 days); meningitis; and acidosis based
on blood Astrup results.
2.2. Statistics. Data were analyzed using standard univariate
and multiple logistic regression analyses as implemented in
the R Programming Language [15]. Most of the covariates
were either binary or continuous. Estimates are also calcu-
lated independently by pregnancy order (Twin 1 or Twin 2)
in order to compare the differences between their risk factors
for ROP andType 1 ROP.The responses and the nonresponses
in the data were completely separated by predicators. Owing
to the phenomenon of separation as described by Heinze
and Schemper [16], the Penalized Maximum Likelihood
Estimation method was implemented to reduce bias for
related parameters as described by both Firth and Heinze
et al. [17, 18]. A stepwise forward selection was used for
choosing covariates for the multivariable analysis. Results
were presented as odds ratios with the corresponding 95%
confidence interval and 𝑃 values. 𝑃 value less than 0.05 was
considered as statistically significant.
3. Results
During the study period, a total of 120 preterm infants of twin
pregnancies were screened. Out of the 120 screened infants,
4 (3.3%) were of non-Chinese ethnicity, 72 infants were
paired twins (60.0%), 1 infant (0.8%) did not survive before
completion of ROP screening, and 1 (0.8%) had insufficient
clinical information. The remaining 68 eligible infants of
paired twins (34 pairs) were included for analysis.
3.1. Demographics. Of these 34 paired twin infants included
in the study, all were of Chinese ethnicity. Eleven pairs were of
different genders and 23 pairs were identical twins. Twenty-
six infants (13 pairs) were the products of IVF and there
was no case of twin-to-twin transfusion. Eighteen twin pairs
underwent Caesarean section and 16 twin pairs had normal
spontaneous deliver. There was no documented evidence of
the use of instrumental delivery from the medical records.
There were 39 male (57.4%) and 29 female (42.6%) subjects.
ThemeanGAwas 30.2± 2.0weeks (range 25.28 to 35.0weeks)
and the mean BW was 1304.9 ± 278.6 grams (range 610.0
to 1950.0 grams). ROP of any stage developed in 9 (13.2%)
infants and Type 1 ROP developed in 2 (2.9%) infants.
The mean GA of the twins was 30.2 ± 2.0 weeks (range
25.28 to 35.0 weeks). Among Twin 1’s, the mean BW was
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Figure 1: Gestational age versus ROP stage in Twins 1 and 2.
1308.9 ± 279.6 grams (range 700.0 to 1950.0 grams). ROP
of any stage developed in 5 (14.7%) infants and Type 1 ROP
developed in 1 (2.9%) infant belonging to Twin 1. Among
Twin 2’s, the mean BW was 1301.0 ± 281.8 grams (range
610.0 to 1720.0 grams). ROP of any stage developed in 4
infants (11.8%) and Type 1 ROP developed in 1 (2.9%) infant
belonging to Twin 2. There was no significant difference in
BW between the 2 twins (𝑃 = 0.4, 𝑡-test).
3.2. Risk Factors for ROP. For ROP development in Twin 1,
a younger GA (OR = 0.44, 𝑃 = 0.02), a higher FiO
2
(OR =
1.34,𝑃 = 0.03), presence of thrombocytopenia (OR= 1429.60,
𝑃 < 0.0001), and IVH (OR = 18.67, 𝑃 = 0.03) were significant
independent risk factors.
For Twin 2, a younger GA (OR = 0.45, 𝑃 = 0.03) was
the only independent risk factor for ROP development and
GA was also the only consistent independent risk factor for
ROP in both Twin 1 and Twin 2. There were no significant
dependent risk factors for ROP development in Twin 1 or
Twin 2 on multivariate analysis (Table 1).
For Type 1 ROP, there were no significant independent
or dependent risk factors found in Twin 1 or Twin 2 on both
univariate and multivariate regression analyses (Table 2).
The relationship between gestational age and birth weight
with ROP staging has been summarized in Figures 1 and 2.
4. Discussion
In univariate analysis, smaller GA was the only independent
risk factor for ROP development irrespective of the order
0.00
200.00
400.00
600.00
800.00
1,000.00
1,200.00
1,400.00
1,600.00
Bo
dy
 w
ei
gh
t (
g)
Body weight versus ROP staging in Twin 1 
ROP stage
1 2 3 4 5
(a)
0.00
200.00
400.00
600.00
800.00
1,000.00
1,200.00
1,400.00
1,600.00
Body weight versus ROP staging in Twin 2 
ROP stage
1 2 3 4 5
Bo
dy
 w
ei
gh
t (
g)
(b)
Figure 2: Body weight versus ROP stage in Twins 1 and 2.
of delivery while the BW was not a significant risk factor.
The significance of GA as a predictor for ROP was consistent
with Woo et al.’s [9] study on discordant twin pairs where
infants with GA ≤ 28 weeks were associated with significantly
(𝑃 < 0.05) higher risk of ROP development, stage 3 ROP, and
threshold ROP requiring laser treatment (76.5%, 52.9%, and
29.4%, resp.) compared to those with GA > 28 weeks (15.8%,
0.0%, and 0.0%, resp.). On the other hand, in a twin pair study
by Azad et al. [8], it was shown that there were no significant
differences in bothGAandBW(𝑃 = 1.00 forGA,𝑃 = 0.39 for
BW) among the twins with severe ROP (mean GA of 29.3 ±
1.3 weeks and mean BW of 1239 ± 206 grams) compared to
those with less severe ROP (mean GA of 29.3 ± 1.3 weeks and
mean BW of 1297 ± 188 grams).
Unlike in previous studies that categorized paired twins
based on ROP severity or BW, we categorized the twins
based on their order of delivery which has not been reported
before in the literature. We feel that this classification is both
clinically relevant for clinicians during their management of
the twins and important for parents who may have questions
about the risk of ROP in their twins. In our study, there
were discrepancies in the susceptibility of postnatal risk
factors for ROP between the twins despite exposure to similar
postnatal conditions. Twin 1 was more likely to develop ROP
when exposed to the following factors that were found to
be independent ROP risk factors in Twin 1 but not Twin
2: presence of IVH, thrombocytopenia, and higher FiO
2
.
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These findings suggest that the first delivered infant of twin
pregnancies may be more prone to develop ROP when
exposed to the above risk factors as compared to the second
infant.This prompts clinicians to be evenmore vigilant when
screening for ROP in the first delivered twin, especially in the
presence of the above risk factors.
A previous study by Prins [19] investigating the postnatal
comorbidities among twins found that the second delivered
infant was associated with higher risks of postnatal com-
plications including intubation and RDS when compared to
their twin. The author postulated that this observation was
partly attributed by the smaller birth weight of the second
twin rather than due to the order of delivery. Wadhawan
et al. [20], on the other hand, found that there was no
difference in neurodevelopmental impairment among twin
pairs regardless of the order of delivery. In our study, there
was no significant difference in BW between Twins 1 and 2
(𝑃 = 0.4); thus, the observed differences in ROP risk factors
among the twins were most probably not related to BW. Our
findings suggest that, in contrast to previous beliefs, Twin 2
was not necessarily the weaker twin and that Twin 1 should
receive an equal amount if not a more vigilant monitoring
and control for the risk factors leading to ROP. Larger scale
prospective cotwin pair studies are warranted to provide an
exact pathophysiological explanation to the differences in
susceptibility to ROP among the twins.
To the best of our knowledge, this is the first study
reporting the incidence and risk factors of ROP and Type 1
ROP in paired twins of Chinese infants based on the order of
delivery.This study serves as a platform for future prospective
and multicenter studies in this area as we anticipate that the
number of preterm twins will likely continue to grow as a
result of the growing demands of assisted reproduction.
Our study had its limitations. Firstly, the retrospective
nature of this study inevitably generates inconsistencies in
data although every effort was made to exclude subjects with
incomplete clinical data. Secondly, subjects were screened
by 3 pediatric ophthalmologists at different time points and
minor interobserver variability can exits, which has not
been objectively accounted for in this study but as all were
trained to follow a strict ROP screening guideline and given
the large population requiring screening, it was the most
optimal balance in terms of providing clinical service and
standardization for research. Lastly, there were only a small
number of infants included in our study due to the rarity of
preterm twins; with over 34 risk factors and only 34 pairs of
twins, the distribution of risk factors among twin pairs were
likely to be uneven and hence negative risk factors should
be interpreted with care taking into account this limitation.
Nevertheless, this study provides important data on the
incidence and risk factors of ROP in the preterm Chinese
infants frompaired twins usingmore updated ROP screening
guidelines than what currently exists in the literature.
5. Conclusion
In preterm, Chinese paired twins, a smaller GA was the
only common independent risk factor for the development of
ROP. The twin that was delivered first was more susceptible
than the other twin to ROP development if they had IVH,
thrombocytopenia, or higher FiO
2
exposure.
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